EMEA-001943-PIP01-16-M02

Key facts

Active substance
ravulizumab
Therapeutic area
Haematology-Hemostaseology
Decision number
P/0199/2019
PIP number
EMEA-001943-PIP01-16-M02
Pharmaceutical form(s)
Concentrate for solution for infusion
Condition(s) / indication(s)
Treatment of atypical haemolytic uremic syndrome
Route(s) of administration
Intravenous use
Contact for public enquiries
Alexion Europe SAS

Tel. +33 147100615
E-mail: pip.enquiries@alexion.com

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating